BioCentury
ARTICLE | Politics, Policy & Law

Health & wealth

BioCentury’s interview with FDA Commissioner Scott Gottlieb

June 24, 2017 1:36 AM UTC

Scott Gottlieb has spent a great deal of time since he left FDA as deputy commissioner in 2007 thinking, writing and talking about ways the agency could do a better job of promoting biomedical innovation. In the first in-depth media interview since he returned to the agency as commissioner, Gottlieb told BioCentury how he plans to turn those ideas into action.

His first steps as commissioner have contradicted predictions from critics that Gottlieb would be too friendly to drug manufacturers. For instance, he quickly announced his intention to take aggressive efforts to stimulate generic competition, and to shut down strategies pharma use to stave off generic and biosimilar competition. ...